Skip to content
  • Saturday, 12 September 2026
  • 6:38 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Pharmaceutical R&D

Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape

Teuku Ryan Apr 25, 2026 0

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…

Read More
Scientists Solve Decade-Old Mystery of Nanoconfined Water Chemistry Through Advanced Machine Learning SimulationsAalto University Researchers Bridge Quantum and Classical Realms by Linking Time Crystals to External Mechanical SystemsThe Architects of the Hive: New Study Reveals Sophisticated Royal Chambers Crucial for Queen Bee DevelopmentScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetLLMOps in 2026: The 10 Tools Every Team Must Have
The oral exposure challenge in PROTACs: What drug developers need to solve earlyAttention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological LandscapeHarmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum InformationSolstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
The oral exposure challenge in PROTACs: What drug developers need to solve early
Lana Keisha Sep 12, 2026
Neuroscience & Brain Research
Attention Unleashed: Rethinking ADHD as a Conduit for Creative Innovation in the Modern Neurological Landscape
Rifan Muazin Sep 12, 2026
Advanced Materials Science
Harmonic Shielding: Harvard Researchers Use Microscopic Sound Waves to Protect Fragile Quantum Information
Nila Kartika Wati Sep 12, 2026
Pharmaceutical R&D
Solstice Oncology Secures $225m in Series A Financing to Advance Neoadjuvant Immuno-Oncology Therapy Porustobart
Teuku Ryan Sep 12, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ